Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 3
2013 1
2014 1
2015 3
2018 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean alexia (12,317 results)?
Tapentadol Prolonged Release: A Review in Pain Management.
Deeks ED. Deeks ED. Drugs. 2018 Nov;78(17):1805-1816. doi: 10.1007/s40265-018-1007-2. Drugs. 2018. PMID: 30471002 Free PMC article. Review.
Tapentadol prolonged release (tapentadol PR) [Palexia() SR in EU] is a long-acting tablet formulation of the strong central analgesic tapentadol, which acts as both a mu-opioid receptor (MOR) agonist and a noradrenaline reuptake inhibitor. ...
Tapentadol prolonged release (tapentadol PR) [Palexia() SR in EU] is a long-acting tablet formulation of the strong central analgesic …
Systematic review of tapentadol in chronic severe pain.
Riemsma R, Forbes C, Harker J, Worthy G, Misso K, Schäfer M, Kleijnen J, Stürzebecher S. Riemsma R, et al. Curr Med Res Opin. 2011 Oct;27(10):1907-30. doi: 10.1185/03007995.2011.611494. Epub 2011 Sep 12. Curr Med Res Opin. 2011. PMID: 21905968 Review.
AIM: A systematic review of chronic pain treatment with strong opioids (step 3 WHO pain ladder) and a comparison to a new drug recently approved for the treatment of severe chronic pain in Europe, tapentadol (Palexia, Nucynta*), were performed. METHODS: Thirteen electronic …
AIM: A systematic review of chronic pain treatment with strong opioids (step 3 WHO pain ladder) and a comparison to a new drug recently appr …
Tapentadol (Palexia) for moderate to severe acute pain.
[No authors listed] [No authors listed] Drug Ther Bull. 2012 Mar;50(3):30-3. doi: 10.1136/dtb.2012.02.0092. Drug Ther Bull. 2012. PMID: 22419754
Tapentadol (Palexia - Grunenthal) is a recently introduced strong analgesic with -agonistic opioid and additional noradrenaline reuptake inhibition properties. ...
Tapentadol (Palexia - Grunenthal) is a recently introduced strong analgesic with -agonistic opioid and additional noradrenaline reupt …
Toxicity of tapentadol: a systematic review.
Channell JS, Schug S. Channell JS, et al. Pain Manag. 2018 Sep 1;8(5):327-339. doi: 10.2217/pmt-2018-0027. Epub 2018 Aug 6. Pain Manag. 2018. PMID: 30079795 Review.
Tapentadol prolonged release for severe chronic pain: results of a noninterventional study involving general practitioners and internists.
Schwittay A, Schumann C, Litzenburger BC, Schwenke K. Schwittay A, et al. J Pain Palliat Care Pharmacother. 2013 Aug;27(3):225-34. doi: 10.3109/15360288.2013.816406. Epub 2013 Aug 19. J Pain Palliat Care Pharmacother. 2013. PMID: 23957433
This noninterventional, prospective study investigated the administration of tapentadol prolonged release (PR; the dosage form described in this article is commercially available in Germany as Palexia retard; Grunenthal GmbH, Aachen) for severe chronic pain in routine clin …
This noninterventional, prospective study investigated the administration of tapentadol prolonged release (PR; the dosage form described in …
Opioid use and harms associated with a sustained-release tapentadol formulation: a postmarketing study protocol.
Peacock A, Larance B, Farrell M, Cairns R, Buckley N, Degenhardt L. Peacock A, et al. BMJ Open. 2018 Mar 23;8(3):e020006. doi: 10.1136/bmjopen-2017-020006. BMJ Open. 2018. PMID: 29574444 Free PMC article.
However, there has been no comprehensive triangulation of data regarding use and harms associated with this formulation. A sustained-release formulation (SRF) of tapentadol (Palexia) was released in Australia in 2011 and listed for public subsidy in 2013. ...
However, there has been no comprehensive triangulation of data regarding use and harms associated with this formulation. A sustained-release …
[Tapentadol prolonged release improves analgesia, functional impairment and quality of life in patients with chronic pain who have previously received oxycodone/naloxone].
Kern KU, Krings D, Waldmann-Rex S. Kern KU, et al. MMW Fortschr Med. 2014 Jul 24;156 Suppl 2:54-63. MMW Fortschr Med. 2014. PMID: 25351028 Clinical Trial. German.
STUDY OBJECTIVE: This subgroup analysis of a prospective, non-interventional study involving general practitioners and internists investigated the administration of tapentadol prolonged release (tapentadol PR; Palexia retard) for the treatment of patients who have previous …
STUDY OBJECTIVE: This subgroup analysis of a prospective, non-interventional study involving general practitioners and internists investigat …
[Clinical practice data regarding tapentadol prolonged release treatment for severe chronic pain - improvement of analgesia, functional competence and quality of life in particular under tapentadol monotherapy].
Lange T, Krings D, Waldmann-Rex S. Lange T, et al. MMW Fortschr Med. 2015 Apr;157(157 Suppl 4):12-21. doi: 10.1007/s15006-015-2932-6. Epub 2015 Apr 8. MMW Fortschr Med. 2015. PMID: 26013114 German.
STUDY OBJECTIVE: To assess effectiveness and tolerability of tapentadol prolonged release (PR, Palexia retard) for the treatment of severe chronic pain under routine clinical practice conditions in Germany. ...
STUDY OBJECTIVE: To assess effectiveness and tolerability of tapentadol prolonged release (PR, Palexia retard) for the treatment of s …
12 results